Ionis, Genuity Science partner to advance RNA-targeted therapies

By The Science Advisory Board staff writers

October 1, 2020 -- Ionis Pharmaceuticals and Genuity Science have entered a multiyear collaboration to accelerate the discovery and development of genetically validated targets for up to 20 diseases.

The partnership will leverage Genuity's whole-genome sequencing and deep phenotypic data to better define underlying disease mechanisms. This will be paired with Ionis' proprietary antisense technology for direct translation of targets into RNA-targeted therapeutics.

Under the agreement, Genuity will receive a combination of upfront payments and development milestones plus product royalties.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.